{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T07:02:27Z","timestamp":1787900547689,"version":"build-2784847793"},"reference-count":122,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.jocn.2014.01.017","type":"journal-article","created":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T08:22:58Z","timestamp":1404202978000},"page":"1857-1865","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 3 Treatment practicalities and recommendations"],"prefix":"10.1016","volume":"21","author":[{"given":"Simon A.","family":"Broadley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Boggild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce J.","family":"Brew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Butzkueven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Heard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Hodgkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan G.","family":"Kermode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette","family":"Lechner-Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.L.","family":"Macdonell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Marriott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah F.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Parratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen W.","family":"Reddel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron P.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Slee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Spies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce V.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor J.","family":"Kilpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela A.","family":"McCombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Willoughby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2014.01.017_b0005","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/1352458507086666","article-title":"Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon","volume":"14","author":"Bosca","year":"2008","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.01.017_b0010","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1177\/1352458512460605","article-title":"Scoring treatment response in patients with relapsing multiple sclerosis","volume":"19","author":"Sormani","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.01.017_b0015","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrneurol.2009.139","article-title":"Predicting responders to therapies for multiple sclerosis","volume":"5","author":"Rio","year":"2009","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.jocn.2014.01.017_b0020","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/1352458507085555","article-title":"Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients","volume":"14","author":"Rio","year":"2008","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.01.017_b0025","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1212\/WNL.0b013e3181dbb51c","article-title":"Freedom from disease activity in multiple sclerosis","volume":"74","author":"Havrdova","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.017_b0030","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(09)70082-1","article-title":"Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis","volume":"8","author":"Rudick","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jocn.2014.01.017_b0035","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1468-1331.2011.03648.x","article-title":"Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response","volume":"19","author":"Rio","year":"2012","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jocn.2014.01.017_b0040","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1017\/S0317167100014244","article-title":"Treatment optimization in MS: Canadian MS Working Group updated recommendations","volume":"40","author":"Freedman","year":"2013","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.jocn.2014.01.017_b0045","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","article-title":"Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group","volume":"45","author":"Johnson","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.017_b0050","first-page":"S44","article-title":"Magnetic resonance imaging techniques to monitor short term evolution of multiple sclerosis and to use in preliminary trials","volume":"64","author":"Miller","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jocn.2014.01.017_b0055","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00415-008-1007-3","article-title":"Switching algorithms: from one immunomodulatory agent to another","volume":"255","author":"Coyle","year":"2008","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2014.01.017_b0060","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000189271","article-title":"Switching to second-line therapies in interferon-beta-treated relapsing-remitting multiple sclerosis patients","volume":"61","author":"Portaccio","year":"2009","journal-title":"Eur Neurol"},{"key":"10.1016\/j.jocn.2014.01.017_b0065","doi-asserted-by":"crossref","first-page":"e59694","DOI":"10.1371\/journal.pone.0059694","article-title":"The Australian Multiple Sclerosis (MS) immunotherapy study: a prospective, multicentre study of drug utilisation using the MSBase platform","volume":"8","author":"Jokubaitis","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jocn.2014.01.017_b0070","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1600-0404.2012.01708.x","article-title":"Stoppers and non-starters of disease-modifying treatment in multiple sclerosis","volume":"127","author":"Grytten","year":"2013","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.jocn.2014.01.017_b0075","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/1352458508096687","article-title":"Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis","volume":"15","author":"Gajofatto","year":"2009","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.01.017_b0080","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1468-1331.2008.02071.x","article-title":"Therapeutic outcome 3years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina","volume":"15","author":"Carra","year":"2008","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jocn.2014.01.017_b0085","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jns.2011.11.010","article-title":"Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-\u03b2 to glatiramer acetate: the Escala Study","volume":"315","author":"Meca-Lallana","year":"2012","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jocn.2014.01.017_b0090","doi-asserted-by":"crossref","first-page":"S227","DOI":"10.1007\/s10072-008-0945-y","article-title":"Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients","volume":"29","author":"Capobianco","year":"2008","journal-title":"Neurol Sci"},{"key":"10.1016\/j.jocn.2014.01.017_b0095","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1600-0404.2006.00627.x","article-title":"Copolymer-1 Treatment Study Principal I. Glatiramer acetate in treatment-na\u00efve and prior interferon-beta-1b-treated multiple sclerosis patients","volume":"113","author":"Zwibel","year":"2006","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.jocn.2014.01.017_b0100","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1468-1331.2010.03112.x","article-title":"Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis","volume":"18","author":"Belachew","year":"2011","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jocn.2014.01.017_b0105","doi-asserted-by":"crossref","first-page":"e16664","DOI":"10.1371\/journal.pone.0016664","article-title":"Switching multiple sclerosis patients with breakthrough disease to second-line therapy","volume":"6","author":"Castillo-Trivino","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jocn.2014.01.017_b0110","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s10072-012-1088-8","article-title":"Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice","volume":"34","author":"Lanzillo","year":"2013","journal-title":"Neurol Sci"},{"key":"10.1016\/j.jocn.2014.01.017_b0115","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/1352458511417481","article-title":"Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis","volume":"18","author":"Prosperini","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.01.017_b0120","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s00415-011-5996-y","article-title":"De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate","volume":"258","author":"Havla","year":"2011","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2014.01.017_b0125","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1007\/s00415-012-6808-8","article-title":"Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis","volume":"260","author":"Havla","year":"2013","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2014.01.017_b0130","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1177\/1352458512464282","article-title":"Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings","volume":"18","author":"Rinaldi","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.01.017_b0135","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1111\/ane.12082","article-title":"Switching from natalizumab to fingolimod: an observational study","volume":"128","author":"Sempere","year":"2013","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.jocn.2014.01.017_b0140","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1212\/01.wnl.0000423208.11698.16","article-title":"Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS","volume":"79","author":"Marousi","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.017_b0145","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1212\/WNL.0b013e318253d61e","article-title":"Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS","volume":"78","author":"Gheuens","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.017_b0150","article-title":"Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning","author":"Martinelli","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.01.017_b0155","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1212\/01.wnl.0000265393.03231.e5","article-title":"Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients","volume":"70","author":"Vellinga","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.017_b0160","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1177\/1352458512463768","article-title":"Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod","volume":"18","author":"Jander","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.01.017_b0165","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jns.2011.05.043","article-title":"Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients","volume":"308","author":"Kerbrat","year":"2011","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jocn.2014.01.017_b0170","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1212\/WNL.0b013e3182698c64","article-title":"Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review","volume":"79","author":"Lu","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.017_b0175","unstructured":"Biogen Idec Australia Pty Ltd., Product Information \u2013 Avonex. Australia: TGA; 28 Jul 2009."},{"key":"10.1016\/j.jocn.2014.01.017_b0180","unstructured":"Biogen Idec NZ Ltd., Data Sheet \u2013 Avonex. Auckland, NZ: Medsafe; 22 Aug 2012."},{"key":"10.1016\/j.jocn.2014.01.017_b0185","unstructured":"Merck Serono Australia Pty Ltd., Product Information \u2013 Rebif. Australia: TGA; 15 Aug 2012."},{"key":"10.1016\/j.jocn.2014.01.017_b0190","unstructured":"Bayer Australia Limited. Product Information \u2013 Betaferon. Australia: TGA; 5 Nov 2010."},{"key":"10.1016\/j.jocn.2014.01.017_b0195","unstructured":"Bayer New Zealand Limited. Data Sheet \u2013 Betaferon. Auckland, NZ: Medsafe; 9 Aug 2010."},{"key":"10.1016\/j.jocn.2014.01.017_b0200","unstructured":"CSL Biotherapies (NZ) Limited. Data Sheet \u2013 Copaxone. Auckland, NZ: Medsafe; 1 Feb 2012."},{"key":"10.1016\/j.jocn.2014.01.017_b0205","unstructured":"CSL Limited. Product Information \u2013 Copaxone. Australia: TGA; 10 Apr 2012."},{"key":"10.1016\/j.jocn.2014.01.017_b0210","unstructured":"Biogen Idec Australia Pty Ltd., Product Information \u2013 Tysabri. Australia: TGA; 26 Nov 2010."},{"key":"10.1016\/j.jocn.2014.01.017_b0215","unstructured":"Biogen Idec NZ Ltd., Data Sheet \u2013 Tysabri. Auckland, NZ: Medsafe; 21 Nov 2012."},{"key":"10.1016\/j.jocn.2014.01.017_b0220","unstructured":"Novartis New Zealand Limited. Data Sheet \u2013 Gilenya. Auckland, NZ: Medsafe; 3 Sep 2012."},{"key":"10.1016\/j.jocn.2014.01.017_b0225","unstructured":"Novartis Pharmaceuticals Australia Pty Limited. Product Information \u2013 Gilenya. Australia: TGA; 11 Oct 2012."},{"key":"10.1016\/j.jocn.2014.01.017_b0230","unstructured":"Sanofi-Aventis Australia Pty Ltd., Product Information \u2013 Aubagio. Australia: TGA; 14 Nov 2012."},{"key":"10.1016\/j.jocn.2014.01.017_b0235","unstructured":"Biogen Idec Australia Pty Ltd., Product Information \u2013 Tecfidera. Australia: TGA; 21 Aug 2013."},{"key":"10.1016\/j.jocn.2014.01.017_b0240","unstructured":"Genzyme Corporation. Prescibing Information \u2013 Campath. US: FDA; 19 Sep 2007."},{"key":"10.1016\/j.jocn.2014.01.017_b0245","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/bdra.20583","article-title":"Early pregnancy azathioprine use and pregnancy outcomes","volume":"85","author":"Cleary","year":"2009","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"10.1016\/j.jocn.2014.01.017_b0250","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/bdra.20399","article-title":"Pregnancy outcome of women exposed to azathioprine during pregnancy","volume":"79","author":"Goldstein","year":"2007","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"10.1016\/j.jocn.2014.01.017_b0255","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1365-2036.2006.03162.x","article-title":"Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy: a Danish nationwide cohort study","volume":"25","author":"Langagergaard","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jocn.2014.01.017_b0260","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1191\/0961203305lu2169oa","article-title":"Cyclophosphamide for lupus during pregnancy","volume":"14","author":"Clowse","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.jocn.2014.01.017_b0265","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1191\/0961203306lu2253xx","article-title":"Cyclophosphamide use and pregnancy in lupus","volume":"15","author":"F\u00e9rnandez","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.jocn.2014.01.017_b0270","first-page":"678","article-title":"Systematic review on the safety of methotrexate in rheumatoid arthritis regarding the reproductive system (fertility, pregnancy, and breastfeeding)","volume":"27","author":"Martinez Lopez","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jocn.2014.01.017_b0275","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.neuro.2006.10.002","article-title":"The first case of mitoxantrone exposure in early pregnancy","volume":"28","author":"De Santis","year":"2007","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.jocn.2014.01.017_b0280","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jns.2011.05.003","article-title":"A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis","volume":"307","author":"Hellwig","year":"2011","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jocn.2014.01.017_b0285","first-page":"69","article-title":"Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation","author":"Armenti","year":"2005","journal-title":"Clin Transpl"},{"key":"10.1016\/j.jocn.2014.01.017_b0290","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1097\/01.tp.0000252683.74584.29","article-title":"Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus","volume":"82","author":"Sifontis","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.jocn.2014.01.017_b0295","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1212\/01.wnl.0000180575.77021.c4","article-title":"The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort","volume":"65","author":"Boskovic","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.017_b0300","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1007\/s00415-008-0909-4","article-title":"Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis?","volume":"255","author":"Patti","year":"2008","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2014.01.017_b0305","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/1352458510394610","article-title":"Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy","volume":"17","author":"Sandberg-Wollheim","year":"2011","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.01.017_b0310","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1212\/01.wnl.0000168905.97207.d0","article-title":"Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis","volume":"65","author":"Sandberg-Wollheim","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.017_b0315","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1212\/WNL.0b013e3181fd62bb","article-title":"Pregnancy and fetal outcomes after interferon-\u03b2 exposure in multiple sclerosis","volume":"75","author":"Amato","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.017_b0320","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s00415-009-5014-9","article-title":"Interferon beta, birth weight and pregnancy in multiple sclerosis","volume":"256","author":"Hellwig","year":"2009","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2014.01.017_b0325","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1177\/1352458511422244","article-title":"Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs","volume":"18","author":"Lu","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.01.017_b0330","series-title":"Postmarketing pregnancy outcomes in patients exposed to intramuscular interferon beta 1a","author":"Tomczyk","year":"2013"},{"key":"10.1016\/j.jocn.2014.01.017_b0335","series-title":"Pregnancy outcomes from the AVONEX\u00ae (interferon beta-1a) pregnancy exposure registry","author":"Tomczyk","year":"2012"},{"key":"10.1016\/j.jocn.2014.01.017_b0340","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/1471-2377-12-124","article-title":"Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study","volume":"12","author":"Giannini","year":"2012","journal-title":"BMC Neurol"},{"key":"10.1016\/j.jocn.2014.01.017_b0345","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1007\/s00415-010-5652-y","article-title":"Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes","volume":"257","author":"Salminen","year":"2010","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2014.01.017_b0350","series-title":"Evaluation of Pregnancy Outcomes from the TYSABRI\u00ae (Natalizumab) Pregnancy Exposure Registry","author":"Cristiano","year":"2013"},{"key":"10.1016\/j.jocn.2014.01.017_b0355","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1177\/1352458511401944","article-title":"Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment","volume":"17","author":"Hellwig","year":"2011","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.01.017_b0360","series-title":"Cumulative data on pregnancy outcomes after exposure to fingolimod","author":"Hellwig","year":"2013"},{"key":"10.1016\/j.jocn.2014.01.017_b0365","series-title":"Updated pregnancy outcomes from the teriflunomide clinical development program: retrospective analysis of the teriflunomide clinical trial database","author":"Kieseier","year":"2013"},{"key":"10.1016\/j.jocn.2014.01.017_b0370","series-title":"Oral BG-12 (dimethyl fumarate) and pregnancy: preclinical studies and pregnancy outcomes reported during the clinical development programme","author":"Gold","year":"2013"},{"key":"10.1016\/j.jocn.2014.01.017_b0375","series-title":"Alemtuzumab advisory committee briefing document","author":"Genzyme Corporation","year":"2013"},{"key":"10.1016\/j.jocn.2014.01.017_b0380","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/bdra.23014","article-title":"A systematic review to calculate background miscarriage rates using life table analysis","volume":"94","author":"Ammon Avalos","year":"2012","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"10.1016\/j.jocn.2014.01.017_b0385","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1177\/1352458510372629","article-title":"Pregnancy outcome in women with multiple sclerosis: results from a prospective nationwide study in Finland","volume":"16","author":"Jalkanen","year":"2010","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.01.017_b0390","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0149-2918(97)80042-2","article-title":"Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis","volume":"19","author":"Munschauer","year":"1997","journal-title":"Clin Ther"},{"key":"10.1016\/j.jocn.2014.01.017_b0395","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1056\/NEJMoa1104318","article-title":"Placebo-controlled trial of oral laquinimod for multiple sclerosis","volume":"366","author":"Comi","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2014.01.017_b0400","first-page":"CD003982","article-title":"Azathioprine for multiple sclerosis","author":"Casetta","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jocn.2014.01.017_b0405","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O\u2019Connor","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2014.01.017_b0410","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","article-title":"Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)","volume":"39","author":"Jacobs","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jocn.2014.01.017_b0415","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/WNL.43.4.655","article-title":"Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group","volume":"43","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.017_b0420","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","article-title":"Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jocn.2014.01.017_b0425","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2014.01.017_b0430","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2014.01.017_b0435","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2014.01.017_b0440","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2014.01.017_b0445","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jocn.2014.01.017_b0450","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jocn.2014.01.017_b0455","first-page":"15","article-title":"Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-1a (AVONEX) therapy","volume":"8","author":"Reess","year":"2002","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.01.017_b0460","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1212\/WNL.50.6.1910","article-title":"Low-dose steroids reduce flu-like symptoms at the initiation of IFNbeta-1b in relapsing-remitting MS","volume":"50","author":"Rio","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.017_b0465","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00127893-200207000-00003","article-title":"Disease-modifying therapy in multiple sclerosis: strategies for optimizing management","volume":"8","author":"Frohman","year":"2002","journal-title":"Neurologist"},{"key":"10.1016\/j.jocn.2014.01.017_b0470","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S0140-6736(86)92730-3","article-title":"Multicentre double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis","volume":"2","author":"Jacobs","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.jocn.2014.01.017_b0475","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1185\/03007990802569455","article-title":"A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events","volume":"25","author":"Brandes","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jocn.2014.01.017_b0480","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000109935","article-title":"Campath-1H treatment of multiple sclerosis","volume":"5","author":"Jones","year":"2008","journal-title":"Neurodegener Dis"},{"key":"10.1016\/j.jocn.2014.01.017_b0485","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0065-2776(08)60297-7","article-title":"Participation of lymphocytes in viral infections","volume":"16","author":"Wheelock","year":"1973","journal-title":"Adv Immunol"},{"key":"10.1016\/j.jocn.2014.01.017_b0490","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1177\/1352458512472750","article-title":"Reduced fingolimod dosage treatment for patients with multiple sclerosis and lymphopenia or neutropenia","volume":"19","author":"Tanaka","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.01.017_b0495","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJM199305063281808","article-title":"Management of fever in patients with cancer and treatment-induced neutropenia","volume":"328","author":"Pizzo","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2014.01.017_b0500","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1212\/01.WNL.0000034080.43681.DA","article-title":"Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial","volume":"59","author":"Panitch","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.017_b0505","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1212\/WNL.63.11_suppl_5.S35","article-title":"Strategies for managing the side effects of treatments for multiple sclerosis","volume":"63","author":"Langer-Gould","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.017_b0510","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(09)70161-5","article-title":"Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project","volume":"10","author":"Carson","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jocn.2014.01.017_b0515","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMc1211805","article-title":"PML in a patient treated with fumaric acid","volume":"368","author":"Ermis","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2014.01.017_b0520","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1056\/NEJMc1215357","article-title":"PML in a patient treated with dimethyl fumarate from a compounding pharmacy","volume":"368","author":"van Oosten","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2014.01.017_b0525","unstructured":"DA Drug Safety Communication: FDA investigating rare brain infection in patient taking Gilenya (fingolimod). FDA; 2013. Available from: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm366529.htm [accessed 1 Nov 2013, 2013]."},{"key":"10.1016\/j.jocn.2014.01.017_b0530","unstructured":"Biogen Idec. Tysabri\u00ae (natalizumab) safety update: 23 August 2013."},{"key":"10.1016\/j.jocn.2014.01.017_b0535","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nrneurol.2010.164","article-title":"Progressive multifocal leukoencephalopathy and other forms of JC virus disease","volume":"6","author":"Brew","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.jocn.2014.01.017_b0540","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/archneurol.2009.31","article-title":"Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study","volume":"66","author":"Boster","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jocn.2014.01.017_b0545","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/j.1468-1331.2011.03597.x","article-title":"Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis","volume":"19","author":"Sahraian","year":"2012","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jocn.2014.01.017_b0550","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases","volume":"9","author":"Clifford","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jocn.2014.01.017_b0555","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1212\/WNL.0b013e31822e55e7","article-title":"Immune reconstitution inflammatory syndrome in natalizumab-associated PML","volume":"77","author":"Tan","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.017_b0560","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1212\/01.wnl.0000338569.32367.3d","article-title":"Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study","volume":"72","author":"O\u2019Connor","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2014.01.017_b0565","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2014.01.017_b0570","doi-asserted-by":"crossref","first-page":"134636","DOI":"10.1155\/2012\/134636","article-title":"Early bilateral cystoid macular oedema secondary to fingolimod in multiple sclerosis","volume":"2012","author":"Liu","year":"2012","journal-title":"Case Rep Med"},{"key":"10.1016\/j.jocn.2014.01.017_b0575","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1742-1241.2011.02721.x","article-title":"Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis","volume":"65","author":"Singer","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jocn.2014.01.017_b0580","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/brain\/aws098","article-title":"Microcystic macular oedema in multiple sclerosis is associated with disease severity","volume":"135","author":"Gelfand","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.jocn.2014.01.017_b0585","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF02427558","article-title":"Occurrence of thyroid autoimmunity in relapsing remitting multiple sclerosis patients undergoing interferon-beta treatment","volume":"19","author":"Martinelli","year":"1998","journal-title":"Ital J Neurol Sci"},{"key":"10.1016\/j.jocn.2014.01.017_b0590","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1474-4422(05)70071-5","article-title":"Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis","volume":"4","author":"Miller","year":"2005","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jocn.2014.01.017_b0595","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria\u201d","volume":"58","author":"Polman","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jocn.2014.01.017_b0600","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(11)70274-5","article-title":"Clinically isolated syndromes","volume":"11","author":"Miller","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jocn.2014.01.017_b0605","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1177\/1352458509107007","article-title":"Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode","volume":"15","author":"Goodin","year":"2009","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2014.01.017_b0610","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1007\/s00415-010-5601-9","article-title":"The radiologically isolated syndrome: take action when the unexpected is uncovered?","volume":"257","author":"Sellner","year":"2010","journal-title":"J Neurol"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586814001830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586814001830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:17:04Z","timestamp":1760822224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586814001830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":122,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0967586814001830"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2014.01.017","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 3 Treatment practicalities and recommendations","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2014.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2014.01.018","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown copyright \u00a9 2014 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}